Finance

Lists
RVTY:BMV
Revvity Inc
MX$1,910.00
0.00%
(0.00) 1D
Jul 27, 9:01:31 AM GMT-6  ·   MXN
All symbols
SymbolPriceChange% Change
Generating top insights for RVTY...
Mkt. cap
14.53B
Avg. vol.
4.00
Volume
0.00
52-wk high
MX$1,910.00
52-wk low
MX$1,644.85
No. of employees
11K
Mkt. cap
14.53B
Avg. vol.
4.00
Volume
0.00
52-wk high
MX$1,910.00
52-wk low
MX$1,644.85
No. of employees
11K
News stories
From web sources and news partners
Profile
Revvity, Inc. is a multinational company headquartered in Waltham, Massachusetts, USA, in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines. In 2022, a split of PerkinElmer resulted in one part, comprising its applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but keeping the PerkinElmer name. The other part, comprising the life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc. From the perspective of Revvity, the goal of creating a separate company was that its businesses might show greater profit margins and more in the way of growth potential. An associated goal was to have more financial flexibility moving forward. On May 16, 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY. Wikipedia
About Revvity Inc
CEOPrahlad Singh
Employees11K
Founded1947
HeadquartersWaltham, Massachusetts, United States
SectorHealth care
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Apr 2026
Jul 2026
Revenue
698.95M
772.06M
711.12M
729.69M
Cost of goods sold
324.34M
350.40M
323.46M
312.82M
Cost of revenue
324.34M
350.40M
323.46M
312.82M
Research and development expenses
50.80M
58.18M
57.89M
48.97M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
227.44M
208.55M
241.91M
243.46M
Operating expense
278.23M
266.73M
299.80M
292.43M
Total operating expenses
602.58M
617.12M
623.26M
605.25M
Operating income
96.37M
154.93M
87.86M
124.44M
Other non operating income
-
-
-
-
EBT including unusual items
55.68M
91.56M
49.99M
63.53M
EBT excluding unusual items
76.49M
133.38M
65.92M
105.36M
Income tax expense
8.46M
-4.21M
9.10M
10.05M
Effective tax rate
15.20%
-4.60%
18.20%
15.82%
Other operating expenses
-
-
-
-
Net income
46.65M
98.36M
40.72M
51.82M
Net profit margin
6.67%
12.74%
5.73%
7.10%
Earnings per share
1.18
1.70
1.06
1.41
Interest and investment income
6.92M
5.75M
6.30M
5.26M
Interest expense
-22.77M
-23.51M
-24.72M
-22.99M
Net interest expenses
-15.85M
-17.76M
-18.41M
-17.73M
Depreciation and amortization charges
-
-
-
-
EBITDA
198.43M
258.01M
192.91M
226.47M
Gain or loss from assets sale
-
-
-5.07M
-
AI content may include mistakes. Learn more
Google apps